Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01721057 · OUTCOME

Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)

A Study in Moderate to Severe Rheumatoid Arthritis Participants · Source last updated 2019-09-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
mm
Interval / dispersion
Standard Deviation
Time frame
Baseline Week 12; Baseline Week 24

What was measured

A second component of the EQ-5D-5L is a self-perceived health score which is assessed using a VAS that ranges from 0 to 100 millimeter (mm), where 0 indicates the worst health you can imagine and 100 indicates the best health you can imagine.

Analysis population: mITT population: all randomized participants who received at least 1 dose of the study drug , with a baseline value and at least 1 post-baseline value. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using mLOCF.

Groups in this outcome

Placebo

Placebo administered orally once daily through Week 24. Participants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.

Baricitinib 2 mg

Baricitinib 2 mg administered orally once daily through Week 24. Participants continued to take background cDMARD therapy throughout study.

Baricitinib 4 mg

Baricitinib 4 mg administered orally once daily through Week 24. Participants will continue to take background cDMARD therapy throughout study.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Placebo216
Baricitinib 2 mg227
Baricitinib 4 mg216

Reported measurements

Self-Perceived Health, Week 12
Values in mm · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Placebo5.723.8Not reportedNot reportedNot reported
Baricitinib 2 mg13.421.8Not reportedNot reportedNot reported
Baricitinib 4 mg11.525.2Not reportedNot reportedNot reported
Self-Perceived Health, Week 24
Values in mm · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Placebo8.425.1Not reportedNot reportedNot reported
Baricitinib 2 mg13.125.8Not reportedNot reportedNot reported
Baricitinib 4 mg10.428.8Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        23.8
        value
        5.7
      2. group Id
        OG001
        spread
        21.8
        value
        13.4
      3. group Id
        OG002
        spread
        25.2
        value
        11.5
    title
    Self-Perceived Health, Week 12
  2. categories
    1. measurements
      1. group Id
        OG000
        spread
        25.1
        value
        8.4
      2. group Id
        OG001
        spread
        25.8
        value
        13.1
      3. group Id
        OG002
        spread
        28.8
        value
        10.4
    title
    Self-Perceived Health, Week 24
denoms
  1. counts
    1. group Id
      OG000
      value
      216
    2. group Id
      OG001
      value
      227
    3. group Id
      OG002
      value
      216
    units
    Participants
description
A second component of the EQ-5D-5L is a self-perceived health score which is assessed using a VAS that ranges from 0 to 100 millimeter (mm), where 0 indicates the worst health you can imagine and 100 indicates the best health you can imagine.
dispersion Type
Standard Deviation
groups
  1. description
    Placebo administered orally once daily through Week 24. Participants continued to take background conventional disease-modifying antirheumatic drug (cDMARD) therapy throughout study.
    id
    OG000
    title
    Placebo
  2. description
    Baricitinib 2 mg administered orally once daily through Week 24. Participants continued to take background cDMARD therapy throughout study.
    id
    OG001
    title
    Baricitinib 2 mg
  3. description
    Baricitinib 4 mg administered orally once daily through Week 24. Participants will continue to take background cDMARD therapy throughout study.
    id
    OG002
    title
    Baricitinib 4 mg
param Type
MEAN
population Description
mITT population: all randomized participants who received at least 1 dose of the study drug , with a baseline value and at least 1 post-baseline value. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using mLOCF.
reporting Status
POSTED
time Frame
Baseline Week 12; Baseline Week 24
title
Change From Baseline in European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) Scores (Self-Perceived Health)
type
SECONDARY
unit Of Measure
mm

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice